Thursday, 22 October 2009

Olmesartan (Benicar), Olmesartan+Hydrochlorthiazide (Benicar HCT) and Olmesartan+ Amlodipine (AZOR) formulations: Innovator got Pediatric exclusivity

Innovator Daiichi has got 6 months pediatric exclusivity for Olmesartan and it's combination products in US market.

The Orange Book patents would expire on following revised dates:

US5616599 (Expiry:Oct 25, 2016): Which covers Olmesartan as product

US6878703 (Expiry:May 19, 2022): which covers combination of Olmesartan with HCTZ

In the light of above extension, the generic version would be delayed by 6 months.

The generic for Olmesartan tablets (Benicar) would be expected after Oct 25, 2016.

The generic version for Olmesartan+ Amlodipine (AZOR) formulations would be expected after Oct 25, 2016.

Further, Olmesartan+Hydrochlorthiazide (Benicar HCT) would be expected after May 19, 2022

Posted by ADKS at 1:01 pm

No comments:

Post a Comment

Subscribe to: Post Comments (Atom)
web page statistics
Disclaimer: "IP Pharma Doc" blog is published for information purpose only. "IP Pharma Doc" blog contains no legal advice. I assume no legal responsibility for the views/information expressed here. “IP Pharma Doc” blog is my personal website and not edited by my employer, accordingly, no part of my blog should be attributed to my employer. All information on the present blog should be double checked for its accuracy and applicability. © Dr. Sarwal (2007)
 
eXTReMe Tracker